Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A.
Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2.
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.
Garmezy B, Schaefer JK, Mercer J, Talpaz M.
Blood Rev. 2021 Jan;45:100691. doi: 10.1016/j.blre.2020.100691. Epub 2020 Apr 7.
MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.
Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, Vannucchi AM.
J Clin Oncol. 2018 Jun 10;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867. Epub 2018 Apr 30.
[Myelofibrosis: A review].
Genthon A, Killian M, Mertz P, Cathebras P, Gimenez De Mestral S, Guyotat D, Chalayer E.
Rev Med Interne. 2021 Feb;42(2):101-109. doi: 10.1016/j.revmed.2020.08.018. Epub 2020 Nov 23.
One thousand patients with primary myelofibrosis: the mayo clinic experience.
Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, Begna KH, Al-Kali A, Ketterling RP, Hanson CA, Pardanani A.
Mayo Clin Proc. 2012 Jan;87(1):25-33. doi: 10.1016/j.mayocp.2011.11.001.
Myelofibrosis biology and contemporary management.
Gangat N, Tefferi A.
Br J Haematol. 2020 Oct;191(2):152-170. doi: 10.1111/bjh.16576. Epub 2020 Mar 20.
Is it primary myelofibrosis or chronic megakaryocytic leukemia?
Lichtman MA.
Haematologica. 2022 Dec 1;107(12):2779-2781. doi: 10.3324/haematol.2022.280838.
Distinguishing autoimmune myelofibrosis from primary myelofibrosis.
Marcellino B, El Jamal SM, Mascarenhas JO.
Clin Adv Hematol Oncol. 2018 Sep;16(9):619-626.
Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A.
Am J Hematol. 2016 Dec;91(12):1262-1271. doi: 10.1002/ajh.24592.
Recent advances in the diagnosis and management of primary myelofibrosis.
Takenaka K, Shimoda K, Akashi K.
Korean J Intern Med. 2018 Jul;33(4):679-690. doi: 10.3904/kjim.2018.033. Epub 2018 Apr 20.
